JP2021518400A5 - - Google Patents

Info

Publication number
JP2021518400A5
JP2021518400A5 JP2020550712A JP2020550712A JP2021518400A5 JP 2021518400 A5 JP2021518400 A5 JP 2021518400A5 JP 2020550712 A JP2020550712 A JP 2020550712A JP 2020550712 A JP2020550712 A JP 2020550712A JP 2021518400 A5 JP2021518400 A5 JP 2021518400A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
hydrogen
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518400A (ja
JP7337086B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052364 external-priority patent/WO2019180683A1/en
Publication of JP2021518400A publication Critical patent/JP2021518400A/ja
Publication of JP2021518400A5 publication Critical patent/JP2021518400A5/ja
Application granted granted Critical
Publication of JP7337086B2 publication Critical patent/JP7337086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550712A 2018-03-23 2019-03-22 スルファメート結合を有するstingモジュレーター化合物、及び製造及び使用の方法 Active JP7337086B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647227P 2018-03-23 2018-03-23
US62/647,227 2018-03-23
US201962821831P 2019-03-21 2019-03-21
US62/821,831 2019-03-21
PCT/IB2019/052364 WO2019180683A1 (en) 2018-03-23 2019-03-22 Sting modulator compounds with sulfamate linkages, and methods of making and using

Publications (3)

Publication Number Publication Date
JP2021518400A JP2021518400A (ja) 2021-08-02
JP2021518400A5 true JP2021518400A5 (cg-RX-API-DMAC7.html) 2022-03-29
JP7337086B2 JP7337086B2 (ja) 2023-09-01

Family

ID=66397323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550712A Active JP7337086B2 (ja) 2018-03-23 2019-03-22 スルファメート結合を有するstingモジュレーター化合物、及び製造及び使用の方法

Country Status (4)

Country Link
US (2) US20210015915A1 (cg-RX-API-DMAC7.html)
EP (2) EP3768685A1 (cg-RX-API-DMAC7.html)
JP (1) JP7337086B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019180683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
PH12020550585A1 (en) 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
MX2023002797A (es) * 2020-09-08 2023-05-04 Univ Texas Composiciones activadoras de sting polivalente y usos de las mismas.
JP7397996B2 (ja) * 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
CA3198433A1 (en) * 2020-11-11 2022-05-19 Wuming YAN Oligonucleotides, reagents and preparation thereof
CN117337292A (zh) 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
CA3267076A1 (en) * 2022-11-09 2024-05-16 Boehringer Ingelheim International Gmbh CYCLIC PYRIDINE DERIVATIVES USED AS CGAS INHIBITORS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
EP3071229A4 (en) * 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
EP3233191A1 (en) 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
DK3233882T3 (da) * 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
IL280430B2 (en) * 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
MX2020006290A (es) * 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.

Similar Documents

Publication Publication Date Title
JP2016509047A5 (cg-RX-API-DMAC7.html)
ES2746374T3 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección producida por el virus del VIH
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2021178873A (ja) Hivカプシド阻害剤のコリン塩形態
JP2021191798A (ja) Hivカプシド阻害剤の固体形態
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2008545660A5 (cg-RX-API-DMAC7.html)
Diana et al. [[(4, 5-Dihydro-2-oxazolyl) phenoxy] alkyl] isoxazoles. Inhibitors of picornavirus uncoating
JP2016510038A5 (cg-RX-API-DMAC7.html)
AU2019351122A1 (en) Inhibitors of VAP-1
JP2022505525A5 (cg-RX-API-DMAC7.html)
RU2019107938A (ru) Производное оксопиколинамида, способ его получения и его фармацевтическое применение
CA2694270A1 (en) Substituted aryloxazoles and the use thereof
JOP20230035A1 (ar) مثبطات apol1 وطرق استخدامها
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
JP2020536082A5 (cg-RX-API-DMAC7.html)
JP2019518046A5 (cg-RX-API-DMAC7.html)
JP2025505200A5 (cg-RX-API-DMAC7.html)
JP2018534355A5 (cg-RX-API-DMAC7.html)
JP2019520344A5 (cg-RX-API-DMAC7.html)
JOP20240120A1 (ar) مشتقات 4-فينيل-2-(1h-3،2،1-تريازول-4-يل) بيبيريدين-4-أول كمثبطات لـ apol1 وطرق استخدامها
JP2018502141A5 (cg-RX-API-DMAC7.html)
RU2003128985A (ru) Производные карбамата для применения для предупреждения или лечения расстройств движений
JP2022529309A5 (cg-RX-API-DMAC7.html)
RU2006130686A (ru) Новые пиперидины в качестве модуляторов хемокинов (ccr)